CN104399044A - Traditional Chinese veterinary medicine for treating arthritis, rheumatoid arthritis and osteoproliferation - Google Patents
Traditional Chinese veterinary medicine for treating arthritis, rheumatoid arthritis and osteoproliferation Download PDFInfo
- Publication number
- CN104399044A CN104399044A CN201410727857.3A CN201410727857A CN104399044A CN 104399044 A CN104399044 A CN 104399044A CN 201410727857 A CN201410727857 A CN 201410727857A CN 104399044 A CN104399044 A CN 104399044A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- veterinary medicine
- arthritis
- chinese veterinary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 66
- 206010039073 rheumatoid arthritis Diseases 0.000 title claims abstract description 35
- 206010003246 arthritis Diseases 0.000 title claims abstract description 24
- 229940079593 drug Drugs 0.000 claims abstract description 34
- 206010005963 Bone formation increased Diseases 0.000 claims description 18
- 241000411851 herbal medicine Species 0.000 claims description 16
- 241000180649 Panax notoginseng Species 0.000 claims description 15
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 15
- 241000208340 Araliaceae Species 0.000 claims description 14
- 241000218176 Corydalis Species 0.000 claims description 14
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 14
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 14
- 235000008434 ginseng Nutrition 0.000 claims description 14
- RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 claims description 14
- 230000000694 effects Effects 0.000 abstract description 27
- 208000002193 Pain Diseases 0.000 abstract description 12
- 230000008961 swelling Effects 0.000 abstract description 9
- 239000008280 blood Substances 0.000 abstract description 6
- 210000004369 blood Anatomy 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 5
- 239000002775 capsule Substances 0.000 abstract description 4
- 208000024891 symptom Diseases 0.000 abstract description 4
- 239000006187 pill Substances 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 241000132012 Atractylodes Species 0.000 abstract 1
- 241000830532 Corydalis yanhusuo Species 0.000 abstract 1
- 241000218671 Ephedra Species 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 235000017443 Hedysarum boreale Nutrition 0.000 abstract 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 abstract 1
- 235000002789 Panax ginseng Nutrition 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 abstract 1
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 abstract 1
- 241000545405 Tripterygium Species 0.000 abstract 1
- 241000331449 Vincetoxicum pycnostelma Species 0.000 abstract 1
- 244000273928 Zingiber officinale Species 0.000 abstract 1
- 235000006886 Zingiber officinale Nutrition 0.000 abstract 1
- 238000010923 batch production Methods 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 235000008397 ginger Nutrition 0.000 abstract 1
- 229930182470 glycoside Natural products 0.000 abstract 1
- 150000002338 glycosides Chemical class 0.000 abstract 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
- 230000003014 reinforcing effect Effects 0.000 abstract 1
- 229910052938 sodium sulfate Inorganic materials 0.000 abstract 1
- 235000011152 sodium sulphate Nutrition 0.000 abstract 1
- 206010042674 Swelling Diseases 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 206010027336 Menstruation delayed Diseases 0.000 description 4
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 229960001680 ibuprofen Drugs 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 2
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 229960000590 celecoxib Drugs 0.000 description 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229960001259 diclofenac Drugs 0.000 description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- -1 indoles) Chemical class 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- SXERGJJQSKIUIC-UHFFFAOYSA-N 2-Phenoxypropionic acid Chemical compound OC(=O)C(C)OC1=CC=CC=C1 SXERGJJQSKIUIC-UHFFFAOYSA-N 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 241000208365 Celastraceae Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 235000000336 Solanum dulcamara Nutrition 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010048873 Traumatic arthritis Diseases 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- ILKJAFIWWBXGDU-MOGDOJJUSA-N amcinonide Chemical compound O([C@@]1([C@H](O2)C[C@@H]3[C@@]1(C[C@H](O)[C@]1(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]13)C)C(=O)COC(=O)C)C12CCCC1 ILKJAFIWWBXGDU-MOGDOJJUSA-N 0.000 description 1
- 229960003099 amcinonide Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- CIWBQSYVNNPZIQ-XYWKZLDCSA-N betamethasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CIWBQSYVNNPZIQ-XYWKZLDCSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229940112801 mobic Drugs 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229960000965 nimesulide Drugs 0.000 description 1
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- JEXVQSWXXUJEMA-UHFFFAOYSA-N pyrazol-3-one Chemical compound O=C1C=CN=N1 JEXVQSWXXUJEMA-UHFFFAOYSA-N 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/17—Gnetophyta, e.g. Ephedraceae (Mormon-tea family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/285—Aucklandia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/37—Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a traditional Chinese veterinary medicine for treating arthritis, rheumatoid arthritis and osteoproliferation. The Chinese veterinary medicine consists of the following crude drugs in parts by weight: 10-20 parts of salvia miltiorrhiza, 8-12 parts of radix aucklandiae, 8-12 parts of corydalis yanhusuo, 8-15 parts of red ginseng, 5-25 parts of large-headed atractylodes, 8-25 parts of tripterygium glycosides, 5-15 parts of ephedra, 10-15 parts of sodium sulfate, 10-20 parts of cynanchum paniculatum, 8-15 parts of licorice root, 10-20 parts of pseudo-ginseng and 5-20 parts of dried ginger. Compared with the prior art, the traditional Chinese veterinary medicine disclosed by the invention has the characteristics of careful selection for the medicinal material, high selectivity, treatment of the symptoms and the causes, high convenience for taking, higher response, easily-accessible raw material and good prospect; the traditional Chinese veterinary medicine has the functions of reinforcing qi and blood, decreasing swelling to relieve pain and removing stasis to dredge stagnancy; after the diseases are cured, the relapse is avoided; the traditional Chinese veterinary medicine can be internally taken by adopting decocted traditional Chinese or can be prepared into pills, capsules and the like and is short in relative treatment course and good in curative effect; the crude drugs are common and easily obtained; the Chinese veterinary medicine is easily prepared and is suitable for batch production. The Chinese veterinary medicine also has the characteristics of short treatment course, good curative effect, high cure rate, greater marker potential and good development and application prospect.
Description
Technical field
The invention belongs to herbal medicine technical field, be specifically related to the herbal medicine of a kind for the treatment of of arthritis, rheumatoid arthritis and hyperosteogeny.
Background technology
Clinical common arthritis mainly comprises following several: rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, gouty arthritis, traumatic arthritis, hyperosteogeny etc.Arthritis general reference occurs in the inflammatory diseases of human synovial and surrounding tissue thereof, and along with the change of life style and natural environment, the scorching phenomenon of joint of animal becomes more and more serious.Clinical manifestation be joint red, swollen, hot, bitterly, functional disorder and joint deformity, severe patient causes joint disabled, affects orthobiosis.At present, the method for the treatment of of arthritis is more, and as " a surname's numbness soup ", " Radix Angelicae Sinensis picks up pain soup " etc., though they have certain curative effect to arthritis, now all Chinese medicine preparation still exist curative effect to rebound slowly, easily, be difficult to the deficiencies such as radical cure, still unsatisfactory.
At present, the Western medicine for the treatment of of arthritis is divided into a line, two wires and three line three classes by people.Except this three classes Western medicine, the Chinese medicine in addition for the treatment of rheumatoid arthritis.
(1) first-line drug, i.e. NSAID (non-steroidal anti-inflammatory drug).First-line drug has good easing pain and diminishing inflammation effect, and the symptoms such as arthroncus, pain, stiff, dysfunction can be made to alleviate rapidly.The first-line drug that treatment rheumatoid arthritis is commonly used comprises: salicylic acid, as aspirin, sodium salicylate etc.; Acetic acid class (i.e. indoles), as indometacin, Sulindac etc.; Phenoxy propionic acid, as ibuprofen (ibuprofen is the slow releasing capsule of ibuprofen), naproxen etc.; Fenamic acids, as flufenamic acid, Diclofenac (its product has Dai Fen, Ying Taiqing, diclofenac) etc.; Former times health class, as piroxicam, meloxicam (trade name mobic) etc.; Pyrazolone, as protected Qin Song, Qiang Bao Qin Song etc.; Former times dry goods, as celecoxib (trade name celecoxib), rofecoxib (trade name ten thousand promise) etc.; Other classes, as nimesulide, nabumetone etc.
(2) Second line Drug onset is slow, the course for the treatment of is long, therefore also referred to as chronic drug.Second line Drug is more trending towards effecting a permanent cure to using of rheumatoid arthritis.This kind of drug main will comprise: the immunosuppressant such as methotrexate, cyclophosphamide, azathioprine, ciclosporin, leflunomide (trade name Ai Ruohua), and sulfasalazine, golden preparation (as Ruide), Beracilline, antimalarial drug etc.
(3) three line medicines, i.e. steroidal anti-inflammatory medicine, be otherwise known as hormone drug.Such medicine has significant curative effect rapidly to the fever of patient with rheumatoid arthritis, arthralgia and swelling.But when using amcinonide, must send for a doctor strictly to grasp dosage and the course for the treatment of, otherwise larger side effect can be produced, lose more than gain.Three conventional line medicines comprise: prednisone, meticortelone, dexamethasone, bent peace Susong, Diprospan etc.
(4) Chinese medicine.Chinese medicine can removing cold and wind damp and hot evil, unclog and readjust meridians joint, reach symptom management, shorten the object of the course of disease, relief of symptoms.
Summary of the invention
The technical problem to be solved in the present invention is current, first-line drug instant effect in the Western medicine for the treatment of joint of animal inflammation, but easily recur, Second line Drug onset is slow, the course for the treatment of is long, three line medicines easily produce toxic and side effects, for solving the problem, the invention provides the herbal medicine of a kind for the treatment of of arthritis, rheumatoid arthritis and hyperosteogeny.
The object of the invention is to realize in the following manner:
A herbal medicine for treatment of arthritis, rheumatoid arthritis and hyperosteogeny, is made up of the crude drug of following weight portion: Radix Salviae Miltiorrhizae 10-20 part, Radix Aucklandiae 8-12 part, Rhizoma Corydalis 8-12 part, Radix Ginseng Rubra 8-15 part, Rhizoma Atractylodis Macrocephalae 5-25 part, Radix Tripterygii Wilfordii 8-25 part, Herba Ephedrae 5-15 part, Natrii Sulfas 10-15 part, Radix Cynanchi Paniculati 10-20 part, Radix Glycyrrhizae 8-15 part, Radix Notoginseng 10-20 part, Rhizoma Zingiberis 5-20 part.
Be made up of the crude drug of following weight portion: Radix Salviae Miltiorrhizae 15 parts, the Radix Aucklandiae 10 parts, Rhizoma Corydalis 10 parts, Radix Ginseng Rubra 12 parts, the Rhizoma Atractylodis Macrocephalae 20 parts, Radix Tripterygii Wilfordii 10 parts, 10 parts, Herba Ephedrae, 10 parts, Natrii Sulfas, Radix Cynanchi Paniculati 15 parts, 12 parts, Radix Glycyrrhizae, Radix Notoginseng 15 parts, Rhizoma Zingiberis 10 parts.
Medicine of the present invention usually adopts and is fried into Chinese medicine decoction and takes orally, and the conventional method of Chinese medicine preparation also can be adopted to be prepared into multiple conventional oral preparations.Such as by above-mentioned formula material medicine pulverize mix homogeneously, pill, capsule or soft extract can be made.The present invention is with Radix Salviae Miltiorrhizae, the Radix Aucklandiae, Rhizoma Corydalis, Radix Tripterygii Wilfordii, Herba Ephedrae, Natrii Sulfas for monarch drug, and Radix Notoginseng, Radix Cynanchi Paniculati, Radix Glycyrrhizae are ministerial drug, and Rhizoma Zingiberis is adjuvant drug, and Radix Salviae Miltiorrhizae, the Rhizoma Atractylodis Macrocephalae, for making medicine, have the effect of dispelling cold by warming the meridian, promoting blood circulation and stopping pain.
Radix Ginseng Rubra is selected to be because Radix Ginseng Rubra is sweet, warm in side of the present invention.There is strongly invigorating primordial QI, nourishing qi to stop, effect that multiple arteries and veins takes off admittedly; The bitter sweet temperature of the Rhizoma Atractylodis Macrocephalae, invigorating the spleen and benefiting QI, dampness diuretic.The pharmacodynamic feature of this two tastes medicine is mainly rich in nutrition, strengthening the tendons and bones, nourishing the liver and kidney, the effect consolidated.
In order to reach effective treatment, treating both the principal and secondary aspects of a disease, this invention medicine also uses the Radix Aucklandiae, Rhizoma Corydalis, Radix Tripterygii Wilfordii, Herba Ephedrae, Natrii Sulfas combination.A few taste medicine focuses on dredge the meridian passage, dispelling cold and removing dampness, eliminate stagnation and dissolve phlegm, reducing swelling and alleviating pain above, and excretion pyretic toxicity, unimpeded blood reaches effect of reducing swelling and alleviating pain.
In order to obtain optimum curative effect, medicine of the present invention also adds Radix Cynanchi Paniculati, Radix Glycyrrhizae, Radix Salviae Miltiorrhizae, Radix Notoginseng and Rhizoma Zingiberis combination on the basis of said medicine.Because Radix Cynanchi Paniculati is warm in nature, there is the effect of removing dampness of dispeling the wind; Radix Glycyrrhizae is sweet flat, the effect of relieving spasm to stop pain; Radix Salviae Miltiorrhizae bitter in the mouth, cold nature; GUIXIN, Liver Channel.Promoting blood flow to regulate menstruation, stasis-dispelling and pain-killing, removing heat from blood eliminating carbuncle, clear away heart-fire relieving restlessness, nourishing blood to tranquillize the mind; Radix Notoginseng is warm in nature, acrid in the mouth, has scattered silt hemostasis, effect of subduing swelling and relieving pain; Rhizoma Zingiberis acrid in the mouth, hot in nature.Return spleen, stomach, the heart, lung meridian, warming spleen and stomach for dispelling cold, recuperating depleted YANG is promoted blood circulation, dampness expectorant, warming the lung to resolve fluid-retention.Above five medicines focus on mediation, alleviate and cushion toxicity and untoward reaction, are aided with effect of Jiedu Yiqi simultaneously.
Above-mentioned 12 taste medicines combine by medicine of the present invention, particularly combine with above-mentioned weight proportion, can reducing swelling and alleviating pain, unimpeded blood, and blood stasis dispelling leads to stagnant, recover effect of function of joint, and the curative effect for the treatment of rheumatoid arthritis is best.The present invention suits the remedy to the case, specificity is strong, treating both the principal and secondary aspects of a disease, evident in efficacy to rheumatoid arthritis, recovers function of joint fast, and once healing, is difficult to recurrence.
The present invention is the herbal medicine of a kind for the treatment of of arthritis, rheumatoid arthritis and hyperosteogeny, compared with prior art, has following characteristics: one is that medical material is selected, and specificity is strong, treating both the principal and secondary aspects of a disease.This invention adopts rich in nutrition, reducing swelling and alleviating pain, logical stagnant by silt, and once healing, is difficult to recurrence.Two is taking conveniences, quick result.This medicine can adopt fried oral medicinal herb, also can be made into pill, capsule etc., relative short treating period, good effect.Three is that raw material is easily got, promise well.These crude drug are common easily to be got, and easily, suitable batch is produced in preparation.Short treating period of the present invention, good effect, cure rate is high, and market potential is large, and development prospect is good.
Detailed description of the invention
Embodiment 1:
A herbal medicine for treatment of arthritis, rheumatoid arthritis and hyperosteogeny, is made up of the crude drug of following weight portion: Radix Salviae Miltiorrhizae 10-20 part, Radix Aucklandiae 8-12 part, Rhizoma Corydalis 8-12 part, Radix Ginseng Rubra 8-15 part, Rhizoma Atractylodis Macrocephalae 5-25 part, Radix Tripterygii Wilfordii 8-25 part, Herba Ephedrae 5-15 part, Natrii Sulfas 10-15 part, Radix Cynanchi Paniculati 10-20 part, Radix Glycyrrhizae 8-15 part, Radix Notoginseng 10-20 part, Rhizoma Zingiberis 5-20 part.
Embodiment 2:
A herbal medicine for treatment of arthritis, rheumatoid arthritis and hyperosteogeny, is made up of the crude drug of following weight portion: Radix Salviae Miltiorrhizae 10g, Radix Aucklandiae 8g, Rhizoma Corydalis 8g, Radix Ginseng Rubra 8g, Rhizoma Atractylodis Macrocephalae 5g, Radix Tripterygii Wilfordii 8g, Herba Ephedrae 5g, Natrii Sulfas 10g, Radix Cynanchi Paniculati 10g, Radix Glycyrrhizae 8g, Radix Notoginseng 10g, Rhizoma Zingiberis 5g.
Embodiment 3:
A herbal medicine for treatment of arthritis, rheumatoid arthritis and hyperosteogeny, is made up of the crude drug of following weight portion: Radix Salviae Miltiorrhizae 12g, Radix Aucklandiae 9g, Rhizoma Corydalis 9g, Radix Ginseng Rubra 9g, Rhizoma Atractylodis Macrocephalae 8g, Radix Tripterygii Wilfordii 12g, Herba Ephedrae 7g, Natrii Sulfas 11g, Radix Cynanchi Paniculati 12g, Radix Glycyrrhizae 9g, Radix Notoginseng 12g, Rhizoma Zingiberis 9g.
Embodiment 4:
A herbal medicine for treatment of arthritis, rheumatoid arthritis and hyperosteogeny, is made up of the crude drug of following weight portion: Radix Salviae Miltiorrhizae 14g, Radix Aucklandiae 10g, Rhizoma Corydalis 10g, Radix Ginseng Rubra 10g, Rhizoma Atractylodis Macrocephalae 12g, Radix Tripterygii Wilfordii 16g, Herba Ephedrae 9g, Natrii Sulfas 12g, Radix Cynanchi Paniculati 14g, Radix Glycyrrhizae 10g, Radix Notoginseng 14g, Rhizoma Zingiberis 12g.
Embodiment 5:
A herbal medicine for treatment of arthritis, rheumatoid arthritis and hyperosteogeny, is made up of the crude drug of following weight portion: Radix Salviae Miltiorrhizae 16g, Radix Aucklandiae 10.5g, Rhizoma Corydalis 10.5g, Radix Ginseng Rubra 12g, Rhizoma Atractylodis Macrocephalae 16g, Radix Tripterygii Wilfordii 20g, Herba Ephedrae 11g, Natrii Sulfas 13g, Radix Cynanchi Paniculati 16g, Radix Glycyrrhizae 12g, Radix Notoginseng 16g, Rhizoma Zingiberis 15g.
Embodiment 6:
A herbal medicine for treatment of arthritis, rheumatoid arthritis and hyperosteogeny, is made up of the crude drug of following weight portion: Radix Salviae Miltiorrhizae 18g, Radix Aucklandiae 11g, Rhizoma Corydalis 11g, Radix Ginseng Rubra 14g, Rhizoma Atractylodis Macrocephalae 20g, Radix Tripterygii Wilfordii 22g, Herba Ephedrae 13g, Natrii Sulfas 14g, Radix Cynanchi Paniculati 18g, Radix Glycyrrhizae 14g, Radix Notoginseng 18g, Rhizoma Zingiberis 17g.
Embodiment 7:
A herbal medicine for treatment of arthritis, rheumatoid arthritis and hyperosteogeny, is made up of the crude drug of following weight portion: Radix Salviae Miltiorrhizae 20g, Radix Aucklandiae 12g, Rhizoma Corydalis 12g, Radix Ginseng Rubra 15g, Rhizoma Atractylodis Macrocephalae 25g, Radix Tripterygii Wilfordii 25g, Herba Ephedrae 15g, Natrii Sulfas 15g, Radix Cynanchi Paniculati 20g, Radix Glycyrrhizae 15g, Radix Notoginseng 20g, Rhizoma Zingiberis 20g.
Embodiment 8:
A herbal medicine for treatment of arthritis, rheumatoid arthritis and hyperosteogeny, is made up of the crude drug of following weight portion: Radix Salviae Miltiorrhizae 15g, Radix Aucklandiae 10g, Rhizoma Corydalis 10g, Radix Ginseng Rubra 12g, Rhizoma Atractylodis Macrocephalae 20g, Radix Tripterygii Wilfordii 10g, Herba Ephedrae 10g, Natrii Sulfas 10g, Radix Cynanchi Paniculati 15g, Radix Glycyrrhizae 12g, Radix Notoginseng 15g, Rhizoma Zingiberis 10g.
Clinical experimental study
1. basic condition
2009 to 2013, Canis familiaris L. Canis familiaris L. 160 example of diagnosis and treatment arthritis, rheumatoid arthritis and hyperosteogeny.Wherein Labrador Retriever 65 example, Sa Moye 55 example, golden hair 40 example; Age 0-1 year 43 example, 1-3 year 54 example, 3-6 year 63 example.Early stage 50 examples in patient with rheumatoid arthritis, mid-term 67 is routine, and late period 43 is routine.
2. diagnostic criteria
To patient with rheumatoid arthritis by medical science by stages universal standard diagnostic classification be in early days, mid-term, late period.
Early stage: most affected joints is to swelling and ache and limitation of activity; But x-ray only shows soft tissue swelling and osteoporosis.
Mid-term: part affected joints functional activity is obviously limited; X-ray film display joint space narrows and bone corrosion in various degree.
Late period: various deformity appears in most affected joints, and fiber is tetanic, movable difficulty, X-ray film display joint heavy damage, dislocation or fusion.
3. Therapeutic Method
The fried Chinese medicine decoction of the prescription provided by embodiment 8 is taken orally.Every day 1 pair, decoct twice, the morning and evening take orally, 30 days courses for the treatment of, treat most elder and take continuously five months 150 days, be i.e. 5 courses for the treatment of.
4. criterion of therapeutical effect
Effective: after treatment, affected joints swells and ache and is clearly better or disappears, function of joint is improved or is recovered normal, and can maintain more than 3 months after drug withdrawal.
Take a turn for the better: after treatment, affected joints pain or swell and ache take a favorable turn.
Invalid: more than treatment 1-3 the course for the treatment of (30 days per courses for the treatment of), affected joints swells and ache without taking a turn for the better.
5. therapeutic outcome
Therapeutic outcome is in table 1 and table 2.
Table 1 Rheumatoid Arthritis after treatment is observed
Table 2 is observed Rheumatoid Arthritis through treating five months
| Rheumatoid arthritis classification | In early days | Mid-term | Late period |
| Case before treatment | 50 | 67 | 43 |
| Case after treatment | 0 | 2 | 4 |
| Total effective rate | 100％ | 97％ | 91％ |
Show from table 1 observation of curative effect result, 5 months are being treated to the dog class suffering from rheumatoid arthritis, observe 5 middle of the month, by Drug therapy rheumatoid arthritis 160 example of the present invention, effective 143 examples of result, obvious effective rate 90%, take a turn for the better 13 examples, and improvement rate is 8%, invalid 4 examples, inefficiency is 2%, and total effective rate reaches 98%.
Show from table 2 observation of curative effect result, medicine of the present invention is to the rheumatoid arthritis dog class 160 example treatment observation of curative effect of 5 months, result is to rheumatoid arthritis early stage patient total effective rate 100%, and mid-term, patient's total effective rate was 97%, and patients with terminal total effective rate is 91%.
On the whole, the present invention has prepared the medicine that a kind of Chinese medicine is used for the treatment of arthritis, rheumatoid arthritis and hyperosteogeny, short treating period of the present invention, good effect, and cure rate is high, and market potential is large, and development prospect is good.
Above-described is only the preferred embodiment of the present invention, it should be pointed out that for a person skilled in the art, and not departing under general idea prerequisite of the present invention, can also make some changes and improvements, these also should be considered as protection scope of the present invention.
Claims (2)
1. a herbal medicine for treatment of arthritis, rheumatoid arthritis and hyperosteogeny, is characterized in that: be made up of the crude drug of following weight portion: Radix Salviae Miltiorrhizae 10-20 part, Radix Aucklandiae 8-12 part, Rhizoma Corydalis 8-12 part, Radix Ginseng Rubra 8-15 part, Rhizoma Atractylodis Macrocephalae 5-25 part, Radix Tripterygii Wilfordii 8-25 part, Herba Ephedrae 5-15 part, Natrii Sulfas 10-15 part, Radix Cynanchi Paniculati 10-20 part, Radix Glycyrrhizae 8-15 part, Radix Notoginseng 10-20 part, Rhizoma Zingiberis 5-20 part.
2. the herbal medicine of a kind for the treatment of of arthritis according to claim 1, rheumatoid arthritis and hyperosteogeny, is characterized in that: be made up of the crude drug of following weight portion: Radix Salviae Miltiorrhizae 15 parts, the Radix Aucklandiae 10 parts, Rhizoma Corydalis 10 parts, Radix Ginseng Rubra 12 parts, the Rhizoma Atractylodis Macrocephalae 20 parts, Radix Tripterygii Wilfordii 10 parts, 10 parts, Herba Ephedrae, 10 parts, Natrii Sulfas, Radix Cynanchi Paniculati 15 parts, 12 parts, Radix Glycyrrhizae, Radix Notoginseng 15 parts, Rhizoma Zingiberis 10 parts.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410727857.3A CN104399044A (en) | 2014-12-01 | 2014-12-01 | Traditional Chinese veterinary medicine for treating arthritis, rheumatoid arthritis and osteoproliferation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410727857.3A CN104399044A (en) | 2014-12-01 | 2014-12-01 | Traditional Chinese veterinary medicine for treating arthritis, rheumatoid arthritis and osteoproliferation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104399044A true CN104399044A (en) | 2015-03-11 |
Family
ID=52636753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410727857.3A Pending CN104399044A (en) | 2014-12-01 | 2014-12-01 | Traditional Chinese veterinary medicine for treating arthritis, rheumatoid arthritis and osteoproliferation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104399044A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1977899A (en) * | 2005-12-03 | 2007-06-13 | 颜正东 | Medicine for treating rheumatoid arthritis |
| WO2007149504A2 (en) * | 2006-06-20 | 2007-12-27 | Metaproteomics, Llc | Isoalpha acid based protein kinase modulation cancer treatment |
-
2014
- 2014-12-01 CN CN201410727857.3A patent/CN104399044A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1977899A (en) * | 2005-12-03 | 2007-06-13 | 颜正东 | Medicine for treating rheumatoid arthritis |
| WO2007149504A2 (en) * | 2006-06-20 | 2007-12-27 | Metaproteomics, Llc | Isoalpha acid based protein kinase modulation cancer treatment |
Non-Patent Citations (1)
| Title |
|---|
| 苏广容等: "理中汤加味治疗类风湿的体会", 《实用中医内科杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103860699A (en) | Pharmaceutical composition for radically treating hypertension, hyperlipidemia and hyperglycemia | |
| CN103182019B (en) | Traditional Chinese medicine composition for treating ROU (recurrent oral ulcer) | |
| CN102133271A (en) | Medicinal tea for treating gout | |
| CN101569739A (en) | Traditional Chinese medicine composition for treating cholecystitis and preparation method thereof | |
| CN105535575A (en) | Medicament to reduce side effects of chemotherapy | |
| CN101658657B (en) | Drug for treating chronic cholecystitis | |
| CN104337989A (en) | Traditional Chinese medicine composition containing centipeda minima and frankincense for treating gout | |
| CN115282229A (en) | Traditional Chinese medicine composition for treating coronary heart disease with syndrome of qi deficiency and blood stasis and preparation method thereof | |
| CN104399044A (en) | Traditional Chinese veterinary medicine for treating arthritis, rheumatoid arthritis and osteoproliferation | |
| CN104740405B (en) | A kind of Chinese medicine preparation and preparation method for treating anaphylactoid purpura renal damage | |
| CN110841007B (en) | Traditional Chinese medicine composition for treating cerebral apoplexy sequela and application thereof | |
| CN103585471B (en) | Traditional Chinese medicine composition for treating thrombocytopenia | |
| CN104606427A (en) | Schefflera arboricola-contained traditional Chinese medicinal composition | |
| CN105287798A (en) | Lipid-lowering and slimming recovery pill | |
| CN104606377A (en) | Traditional Chinese medicinal composition for treating gastritis | |
| CN105327024A (en) | Traditional Chinese medicine preparation for treating rheumatoid arthritis | |
| CN104587122A (en) | Traditional Chinese medicine composition for treating chronic gastritis | |
| CN104826068A (en) | Medicine for expelling wind and eliminating dampness and preparation method of medicine | |
| CN104524540A (en) | Traditional Chinese medicine composition for treating gallbladder polyps | |
| CN104606426A (en) | Traditional Chinese medicinal composition preparation for treating chronic gastritis and preparation method thereof | |
| CN104173952A (en) | Traditional Chinese medicine composition for treating benign ovarian tumor | |
| CN103301309A (en) | Traditional Chinese herbal medicine for treating laryngocarcinoma and esophagus cancer | |
| CN110742955A (en) | Traditional Chinese medicine composition for treating lumbago | |
| CN102028810A (en) | Traditional Chinese medicine for treating lumbar intervertebral disc protrusion | |
| CN108888743A (en) | It is a kind of for treating the Chinese medicine composition of pectoralgia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150311 |
|
| RJ01 | Rejection of invention patent application after publication |